Home / Specialties / Geriatric Medicine / Are SGLT2 Inhibitors Safe After 75? New Research Challenges Common Concerns

Are SGLT2 Inhibitors Safe After 75? New Research Challenges Common Concerns

Nov 21, 2026
272 views
 

For adults over 75, diabetes treatment involves more than lowering blood sugar. Clinicians must also consider falls, dehydration, kidney health, and treatment burden. New Canadian research offers encouraging safety findings for SGLT2 inhibitors in older adults, although individual risks still matter. However, the findings call for careful interpretation, not blanket prescribing.

Table of Contents

  • SGLT2 Inhibitors in Older Adults: What the Study Found
  • Why Observational Safety Results Need Context
  • Frailty, Kidney Function, and Hydration Risks
  • Individualizing SGLT2 Treatment After Age 75
  • Conclusion
  • Frequently Asked Questions

SGLT2 Inhibitors in Older Adults: What the Study Found

Published in Diabetes Care in October 2026, the Canadian cohort study examined adults aged 75 or older with type 2 diabetes. Researchers used British Columbia health records for people starting treatment between January 2021 and December 2023. They compared 4,997 new SGLT2 inhibitor users with 1,289 new DPP-4 inhibitor users. Median ages were 79 and 82 years, respectively.

 

The SGLT2 group had a 24% lower relative hazard of acute kidney injury (hazard ratio 0.76; 95% confidence interval 0.60–0.95). Additionally, its hazard of all-cause hospitalization was 13% lower (0.87; 95% CI 0.77–0.98). These are adjusted associations, not proof that treatment prevented either outcome.

Researchers detected no clear differences in infections, diabetic ketoacidosis, falls, or fractures. Importantly, some estimates were imprecise, so clinically important harm cannot be excluded.

DPP-4 inhibitors, including sitagliptin (Januvia), are often viewed as easier to tolerate in later life. Meanwhile, SGLT2 agents include empagliflozin (Jardiance) and dapagliflozin (Farxiga). These drugs offer heart and kidney benefits for selected patients.

Consequently, this comparison provides useful information for clinicians who must balance potential benefits against medication-related risks in older patients.

Why Observational Safety Results Need Context

The study examined real-world prescribing, not randomized treatment assignments. Investigators used statistical weighting to address measured differences between groups. Nevertheless, unmeasured health factors may have shaped both the prescription and the results.

For example, clinicians might avoid SGLT2 treatment in someone with poor fluid intake or recurrent dizziness. Patients starting DPP-4 therapy were also older on average, and more were women. Although statistical adjustment helps account for these differences, it cannot remove every potential bias.

Moreover, "no detected difference" does not mean that two treatments have identical risks. Rare events, especially diabetic ketoacidosis, are difficult to measure precisely. A study may lack enough events to detect a meaningful difference, even when one exists.

Therefore, the results do not prove that every patient over 75 benefits from treatment. The findings also do not establish that these medications are safer than every other diabetes treatment for people over 75.

Instead, the key lesson is that age alone should not automatically rule out this drug class. Clinicians should consider the overall evidence, individual health conditions, and the patient's ability to manage treatment safely.

Frailty, Kidney Function, and Hydration Risks

SGLT2 medicines increase glucose loss through urine and may increase urine volume. As a result, dehydration, low blood pressure, and dizziness need attention, especially in people taking diuretics.

Frailty, mobility problems, or difficulty accessing fluids can further increase risk. Older patients who depend on caregivers for meals, medications, or hydration may require additional monitoring.

The Diabetes in Control guide to dehydration and blood sugar explains why maintaining hydration and understanding sick-day precautions matter.

Kidney assessment is equally important. Clinicians should review estimated glomerular filtration rate (eGFR), blood pressure, kidney trends, and the reason for treatment.

Although a small early eGFR dip may occur after starting therapy, this does not necessarily signal kidney injury. Furthermore, prescribing thresholds depend on the specific drug and whether the goal is glucose control, heart failure care, or kidney protection.

Genital yeast infections remain a recognized risk despite the study's neutral overall infection finding. Rare ketoacidosis may also occur without extremely high glucose levels.

Therefore, patients need clear instructions for vomiting, poor intake, fever, surgery, or prolonged fasting. The 2026 American Diabetes Association guidance specifically recommends caution with frailty and volume depletion.

Recognizing these risks does not mean SGLT2 therapy should be avoided in every older patient. Instead, appropriate patient selection and follow-up can help clinicians identify those most likely to benefit.

Individualizing SGLT2 Treatment After Age 75

The practical question is whether a specific patient stands to gain more benefit than burden. Someone with heart failure or chronic kidney disease may benefit beyond A1C reduction.

By contrast, repeated falls, very low blood pressure, or poor access to fluids may favor another treatment plan. Patients with several chronic conditions may also need closer monitoring when medications change.

Before prescribing, clinicians should review other drugs, kidney tests, blood pressure, infection history, nutrition, and care goals.

Next, discussing likely benefits alongside urinary symptoms, medication costs, and the ability to follow sick-day instructions can help patients make informed decisions.

After starting treatment, clinicians should reassess fluid status, symptoms, and kidney function based on individual risk. Any diuretic change or temporary medication pause should be coordinated with the care team.

Earlier Diabetes in Control coverage of SGLT2 use in geriatric patients offers another comparison with a different treatment class.

Because studies evaluate different populations and outcomes, their findings may vary. This reinforces the importance of using research as one part of a broader clinical assessment.

Ultimately, clinicians should weigh the potential benefits of these medications against each patient's health risks, treatment goals, and personal preferences.

Conclusion

The Canadian findings offer some reassurance about the safety of SGLT2 inhibitor treatment for patients over 75. Compared with DPP-4 inhibitors, initiation was associated with less acute kidney injury and fewer hospitalizations, without clear differences in several other measured harms.

Still, observational evidence cannot guarantee safety for an individual. Frailty, hydration, kidney function, and treatment goals remain essential when choosing diabetes medications.

For clinicians, the findings support a more individualized approach rather than excluding patients based on age alone.

Frequently Asked Questions

Are SGLT2 inhibitors safe for everyone over 75?

No. Age alone is not a contraindication, but frailty, blood pressure, kidney function, and other medications affect treatment decisions. Clinicians should assess each patient's overall health before prescribing.

Did the Canadian study prove these drugs prevent kidney injury?

No. Researchers found an association with lower acute kidney injury risk compared with DPP-4 treatment. However, the observational study cannot establish that the medications directly caused this benefit.

Do SGLT2 drugs increase the risk of falls in older adults?

The study found no clear difference in falls between treatment groups. However, dehydration and low blood pressure may increase fall risk in some patients, particularly those with frailty or mobility problems.

Which symptoms require medical attention during SGLT2 treatment?

Persistent dizziness, poor fluid intake, or signs of infection warrant medical review. Symptoms suggesting ketoacidosis, such as nausea, vomiting, abdominal pain, or unusual weakness, require urgent assessment, even when blood glucose is not extremely high.

Should older adults stop SGLT2 inhibitors during illness?

Many sick-day plans recommend temporarily pausing these medications during significant illness or reduced food and fluid intake. However, patients should follow individualized instructions from their healthcare team. Those needing additional guidance can find healthcare professionals through Healthcare.pro.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.